» Articles » PMID: 12530340

Risperidone in the Treatment of Hispanic Inpatients with Schizophrenia: a Pilot Study

Overview
Journal Psychiatry
Specialty Psychiatry
Date 2003 Jan 18
PMID 12530340
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

A growing body of scientific evidence over the last two decades suggests that certain ethnic groups may require lower dosages of standard antipsychotics for the treatment of schizophrenia symptoms. Recent studies have implicated the role of genetic and environmental factors in the metabolism of these drugs as the basis for this differential response. In this pilot study, 10 Hispanic and 8 non-Hispanic patients with schizophrenia were enrolled in a double-blind, parallel-group, inpatient risperidone dosing (daily versus twice daily) trial with the novel antipsychotic risperidone. The result of repeated measures ANOVA reveals a significant interaction effect for race, indicative of a faster rate of symptom improvement (PANSS General) in Hispanic patients. The findings suggest that this novel agent may be preferable for certain ethnic groups. A trend toward more frequently occurring extrapyramidal symptoms among Hispanics was also found, which suggests that dosages lower than those typically recommended may be necessary in Hispanic schizophrenics.

Citing Articles

Differences in metabolic biomarkers in people with schizophrenia who are of Mexican descent compared to non-Hispanic whites.

Kwak P, Ibarra C, Hernandez A, Carrasco J, Sears D, Jeste D Psychiatry Res. 2024; 334:115788.

PMID: 38401486 PMC: 11249025. DOI: 10.1016/j.psychres.2024.115788.


Differences in Total Score of Positive and Negative Syndrome Scale between Bataknese and Javanese Men with Schizophrenia Receiving Risperidone Treatment.

Pardosi M, Loebis B, Husada M, Nasution N, Effendy E, Amin M Open Access Maced J Med Sci. 2019; 7(14):2292-2297.

PMID: 31592006 PMC: 6765072. DOI: 10.3889/oamjms.2019.665.


Efficacy of Naltrexone for the Treatment of Alcohol Dependence in Latino Populations.

Lopez C, Barr S, Reid-Quinones K, de Arellano M J Stud Alcohol Drugs. 2017; 78(4):629-634.

PMID: 28728646 PMC: 5551667. DOI: 10.15288/jsad.2017.78.629.


Use of risperidone long-acting injectable in a rural border community clinic in southern california.

Camacho A, Ng B, Galangue B, Feifel D Psychiatry (Edgmont). 2009; 5(6):43-9.

PMID: 19727284 PMC: 2695749.


Ethnic variation in symptoms and response to risperidone in youths with schizophrenia-spectrum disorders.

Patel N, Crismon M, Shafer A, De Leon A, Lopez M, Lane D Soc Psychiatry Psychiatr Epidemiol. 2006; 41(5):341-6.

PMID: 16467950 DOI: 10.1007/s00127-006-0036-4.